MWNA
MDNA

Marshall Wace North America’s Medicenna Therapeutics Corp. Common Shares MDNA Stock Holding History

Marshall Wace North America’s Portfolio MDNA Stock Details MDNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-19,300
Closed -$79K – 1881
2021
Q1 		$79K Buy
+19,300
New +$78.6K ﹤0.01% 1447

Other funds holding MDNA

AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
BOTOTLSJU
Board of Trustees of The Leland Stanford Junior University Redwood City, California $849M AUM 55.45% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return
IIM
Intact Investment Management Montreal, Quebec, Canada $3.52B AUM 37.29% 1-Year Est. Return
ACM
ACT Capital Management Wayne, Pennsylvania $153M AUM
WVP
Worth Venture Partners Fort Lee, New Jersey $31.6M AUM 28.5% 1-Year Est. Return
TAM
Tocqueville Asset Management New York $6.74B AUM 32.29% 1-Year Est. Return
MS
Maven Securities St Helier, Jersey $5.2B AUM 44.01% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Marshall Wace North America's MDNA Position: Q2 2021 in Review

Marshall Wace North America sold out of Medicenna Therapeutics Corp. Common Shares (MDNA) in Q2 2021, closing a stake of 19,300 shares — an estimated $79K sold.

Marshall Wace North America first reported a position in MDNA in Q1 2021 and held it in 1 quarter. The position peaked at $79K in Q1 2021. 26 funds tracked by Wall St. Rank hold MDNA as of Q2 2021.

  • Marshall Wace North America reported no remaining Medicenna Therapeutics Corp. Common Shares position as of Q2 2021 after selling out during the quarter.
  • Marshall Wace North America sold 19,300 Medicenna Therapeutics Corp. Common Shares shares in Q2 2021, an estimated $79K.
  • Marshall Wace North America first reported a position in Medicenna Therapeutics Corp. Common Shares in Q1 2021 and held it in 1 quarter.
  • Marshall Wace North America's Medicenna Therapeutics Corp. Common Shares position peaked at $79K in Q1 2021.
  • 26 funds tracked by Wall St. Rank held Medicenna Therapeutics Corp. Common Shares as of Q2 2021.

Based on Marshall Wace North America's 13F filing for Q2 2021, filed 13 Aug 2021.